Gene Signature to Identify Patients Who Will Benefit from Tamoxifen Therapy
the Cancer Therapy Advisor take:
Recent research published in Cancer Research, the journal of the American Associated for Cancer Research, has identified a gene signature that has the potential to identify patients that will benefit from tamoxifen therapy.
Rene Bernards, PhD, cofounder of Agendia, Inc., conducted the study that drew upon data involving approximately 680 patients with estrogen receptor¬–positive breast cancer. Estrogen receptor–positive disease comprises about 70% of patients with breast cancer.
Currently, tamoxifen is effective in reducing the risk of cancer in most of this subset of patients, but not everyone responds positively to the treatment. By identifying patients who will respond, those who don’t respond to treatment will not be unnecessarily subjected to potential risks and side effects, which include menopausal-like symptoms such as hot flashes, vaginal dryness, and loss of libido as well as less common but more serious risks such as endometrial cancer and blood clots.
Dr. Bernards and colleagues indentified and tested a gene signature that is associated with the loss of function of a gene called USP9X. According to their research, tamoxifen resistance occurs when USP9X loses function in the breast cancer cell.
The gene signature was able to identify tamoxifen-resistance in patients in two large cohorts. Dr. Bernards and colleagues are not working to validate these results using data from a prospective randomized controlled trial that should be completed by the end of the year.
A gene signature has potential to identify which patients will benefit from tamoxifen therapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models